

# 2024 IHS Diabetes Care and Outcome Audit Results







The majority of Audit sites are Tribal programs<sup>1</sup>

**82** IHS Facilities

**29** Urban Indian Organizations



**324** facilities submitted data to the Audit




1997 to 2024  
**Mean A1C**  
↓ 12%  
to 7.72%<sup>2</sup>



1998 to 2024  
**Mean LDL cholesterol**  
↓ 28%  
to 86 mg/dL<sup>2</sup>




2008-2024  
**Percentage of people with mean BP <140/<90**  
↑ 6% to 69%<sup>2</sup>



2008 to 2024  
**Metformin remains the most commonly used medication.<sup>2</sup>**

There have been steady increases in the use of GLP-1 receptor agonists and SGLT-2 inhibitors over the last 10 years.



2013 to 2024  
**Significant improvement in CVD risk reduction measures.<sup>2</sup>**

- Target BP <130/<80 added in 2024 to align with ADA Recommendation.
- Antiplatelet therapy data may not reflect over-the-counter aspirin use.